Sucampo is a global biopharmaceutical company that is built on the ongoing pursuit of scientific innovation and an unwavering passion for improving the lives of patients.
We seek partnerships that allow us to deliver on our mission to use scientific innovation to improve the lives of patients, their families and caregivers.
Developing strategic partnerships is a cornerstone of our business philosophy, allowing us to match our expertise with the knowledge and capabilities of others to create, access and deliver the most needed and innovative pharmaceutical treatments.
Sucampo is a proven partner, with a track record of providing value to the companies we work with. We are actively exploring an expansion of
our collaborations and are open to working with all types of partners or opportunities.
For Business Development inquiries please contact:
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.